{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:06:40Z","timestamp":1789538800674,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-026-04797-z","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:57:15Z","timestamp":1789538235000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant therapy in thyroid cancer: an emerging approach"],"prefix":"10.1007","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2742-7085","authenticated-orcid":false,"given":"Fabi\u00e1n","family":"Pitoia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7450-5832","authenticated-orcid":false,"given":"In\u00e9s","family":"Califano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5436-3649","authenticated-orcid":false,"given":"Marika","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8893-9703","authenticated-orcid":false,"given":"David","family":"Shonka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2125-4937","authenticated-orcid":false,"given":"Pierpaolo","family":"Trimboli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5372-0982","authenticated-orcid":false,"given":"Laura","family":"Fugazzola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5373-9181","authenticated-orcid":false,"given":"Gregory","family":"Randolph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"4797_CR1","doi-asserted-by":"publisher","first-page":"e240185","DOI":"10.1530\/ERC-24-0185","volume":"32","author":"I Califano","year":"2025","unstructured":"I. Califano, G. Randolph, F. Pitoia, Transforming thyroid cancer management: the impact of neoadjuvant therapy. Endocr. Relat. Cancer. 32, e240185 (2025). https:\/\/doi.org\/10.1530\/ERC-24-0185","journal-title":"Endocr. Relat. Cancer"},{"key":"4797_CR2","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1089\/thy.2019.0133","volume":"29","author":"JR Wang","year":"2019","unstructured":"J.R. Wang, M.E. Zafereo, R. Dadu et al., Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAF V600E-mutated anaplastic thyroid carcinoma. Thyroid. 29, 1036\u20131043 (2019). https:\/\/doi.org\/10.1089\/thy.2019.0133","journal-title":"Thyroid"},{"key":"4797_CR3","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1089\/thy.2022.0504","volume":"33","author":"X Zhao","year":"2023","unstructured":"X. Zhao, J.R. Wang, R. Dadu et al., Surgery after BRAF-directed therapy is associated with improved survival in BRAF V600E-mutant anaplastic thyroid cancer: a single-center retrospective cohort study. Thyroid. 33, 484\u2013491 (2023). https:\/\/doi.org\/10.1089\/thy.2022.0504","journal-title":"Thyroid"},{"key":"4797_CR4","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1089\/thy.2023.0573","volume":"34","author":"S Hamidi","year":"2024","unstructured":"S. Hamidi, P.C. Iyer, R. Dadu et al., Checkpoint inhibition in addition to dabrafenib\/trametinib for BRAF V600E-mutated anaplastic thyroid carcinoma. Thyroid. 34, 336\u2013346 (2024). https:\/\/doi.org\/10.1089\/thy.2023.0573","journal-title":"Thyroid"},{"key":"4797_CR5","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1002\/hed.27735","volume":"46","author":"M Russell","year":"2024","unstructured":"M. Russell, M.L. Gild, L.J. Wirth et al., Neoadjuvant therapy to improve resectability of advanced thyroid cancer: a real-world experience. Head Neck. 46, 2496\u20132507 (2024). https:\/\/doi.org\/10.1002\/hed.27735","journal-title":"Head Neck"},{"key":"4797_CR6","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1089\/thy.2024.0090","volume":"34","author":"F Pitoia","year":"2024","unstructured":"F. Pitoia, E. Abelleira, A. Roman-Gonzalez et al., Neoadjuvant treatment of locally advanced thyroid cancer: a preliminary Latin American experience. Thyroid. 34, 949\u2013952 (2024). https:\/\/doi.org\/10.1089\/thy.2024.0090","journal-title":"Thyroid"},{"key":"4797_CR7","unstructured":"G. Randolph, M. Russell, A.A. Ahmed et al., Results of a phase 2 study of neoadjuvant lenvatinib in locally advanced invasive differentiated thyroid cancer. Thyroid 35, e1-e63 (2025). Abstract presented at the 94th Annual Meeting of the American Thyroid Association, Scottsdale, AZ, USA"},{"key":"4797_CR8","unstructured":"M.E. Zafereo, M.E. Cabanillas, A. Maniakas et al., Neoadjuvant treatment with selpercatinib for RET-altered thyroid cancer: a multicenter phase 2 clinical trial. Thyroid 35, e1-e63 (2025). Abstract Oral 009 presented at the 94th Annual Meeting of the American Thyroid Association, Scottsdale, AZ, USA"},{"key":"4797_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/hed.70221","author":"JJ Santiva\u00f1ez","year":"2026","unstructured":"J.J. Santiva\u00f1ez, C. Betancourt, C. Garcia et al., Lenvatinib as neoadjuvant therapy in locally advanced thyroid cancer: CT-based selection and outcomes from a 23-patient cohort. Head Neck. (2026). https:\/\/doi.org\/10.1002\/hed.70221","journal-title":"Head Neck"},{"key":"4797_CR10","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/cen.70054","volume":"104","author":"A Dorman","year":"2026","unstructured":"A. Dorman, G. Shendler, A. Warshavsky et al., Surgical outcomes following neoadjuvant-targeted therapy for advanced differentiated thyroid cancer: real-world data. Clin. Endocrinol. (Oxf). 104, 270\u2013280 (2026). https:\/\/doi.org\/10.1111\/cen.70054","journal-title":"Clin. Endocrinol. (Oxf)"},{"issue":"1","key":"4797_CR11","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s12020-026-04694-5","volume":"91","author":"A Smulever","year":"2026","unstructured":"A. Smulever, F. Pitoia, E. Abelleira, I. Califano, Anaplastic thyroid carcinoma in Argentina: real-world diagnostic lags and treatment barriers. Endocrine. 91(1), 229 (2026). https:\/\/doi.org\/10.1007\/s12020-026-04694-5","journal-title":"Endocrine"},{"key":"4797_CR12","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1177\/10507256251363120","volume":"35","author":"MD Ringel","year":"2025","unstructured":"M.D. Ringel, J.A. Sosa, Z. Baloch et al., 2025 American Thyroid Association management guidelines for adult patients with differentiated thyroid cancer. Thyroid. 35, 841\u2013985 (2025). https:\/\/doi.org\/10.1177\/10507256251363120","journal-title":"Thyroid"},{"key":"4797_CR13","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1002\/hed.27025","volume":"44","author":"DC Shonka Jr","year":"2022","unstructured":"D.C. Jr Shonka, A. Ho, A.V. Chintakuntlawar et al., American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: defining advanced thyroid cancer and its targeted treatment. Head Neck. 44, 1277\u20131300 (2022). https:\/\/doi.org\/10.1002\/hed.27025","journal-title":"Head Neck"},{"key":"4797_CR14","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1177\/10507256251367286","volume":"35","author":"J Bauzon","year":"2025","unstructured":"J. Bauzon, G. Ponce de Leon-Ballesteros, E. Lincango et al., Neoadjuvant therapy with multikinase inhibitors for locally advanced differentiated thyroid cancer: a systematic review. Thyroid. 35, 1108\u20131119 (2025). https:\/\/doi.org\/10.1177\/10507256251367286","journal-title":"Thyroid"},{"key":"4797_CR15","unstructured":"ClinicalTrials.gov, Zanzalintinib for the treatment of advanced thyroid cancer before surgery. ClinicalTrials.gov identifier: NCT06959511. Accessed 6 July 2026."},{"key":"4797_CR16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1089\/thy.2022.0506","volume":"33","author":"KJ Contrera","year":"2023","unstructured":"K.J. Contrera, M.K. Gule-Monroe, M.I. Hu et al., Neoadjuvant selective RET inhibitor for medullary thyroid cancer: a case series. Thyroid. 33, 129\u2013132 (2023). https:\/\/doi.org\/10.1089\/thy.2022.0506","journal-title":"Thyroid"},{"key":"4797_CR17","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","volume":"21","author":"K Tsuchikama","year":"2024","unstructured":"K. Tsuchikama, Y. Anami, S.Y.Y. Ha, C.M. Yamazaki, Exploring the next generation of antibody-drug conjugates. Nat. Rev. Clin. Oncol. 21, 203\u2013223 (2024). https:\/\/doi.org\/10.1038\/s41571-023-00850-2","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"4797_CR18","doi-asserted-by":"publisher","DOI":"10.1080\/1061186X.2026.2687011","author":"I Ali","year":"2026","unstructured":"I. Ali, M. Faiza, A. Mehmood et al., Integrating antibody-drug conjugates, multispecific antibodies, targeted protein degradation, and nanomedicine in precision oncology. J. Drug Target. (2026). https:\/\/doi.org\/10.1080\/1061186X.2026.2687011","journal-title":"J. Drug Target."},{"key":"4797_CR19","doi-asserted-by":"publisher","first-page":"e70209","DOI":"10.1002\/hon.70209","volume":"44","author":"K Liu","year":"2026","unstructured":"K. Liu, V.T. Pham, S. Fu et al., CAR T cell therapy in solid tumors: lessons from early-phase clinical trials and biological barriers to efficacy. Hematol. Oncol. 44, e70209 (2026). https:\/\/doi.org\/10.1002\/hon.70209","journal-title":"Hematol. Oncol."},{"key":"4797_CR20","doi-asserted-by":"publisher","first-page":"1479483","DOI":"10.3389\/fimmu.2024.1479483","volume":"15","author":"M Skalickova","year":"2025","unstructured":"M. Skalickova, K. Hadrava Vanova, O. Uher et al., Injecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer. Front. Immunol. 15, 1479483 (2025). https:\/\/doi.org\/10.3389\/fimmu.2024.1479483","journal-title":"Front. Immunol."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04797-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-026-04797-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04797-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:57:17Z","timestamp":1789538237000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-026-04797-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4797"],"URL":"https:\/\/doi.org\/10.1007\/s12020-026-04797-z","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"assertion":[{"value":"6 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"302"}}